Targovax
133 articles about Targovax
-
Targovax: Invitation To First Quarter 2017 Results Presentation Tuesday 25 April
4/19/2017
-
Targovax To Present Clinical Data On Its Phase I/II Clinical Trial Evaluating TG01 In Resected Pancreatic Cancer At The ASCO Annual Meeting
4/6/2017
-
Targovax: Invitation To Second Quarter 2016 Results Presentation Thursday 25 August
8/15/2016
-
Targovax Appoints Two New Directors To Its Board
9/15/2015
-
ASCO15: Targovax Releases TGO1 RAS-Mutation-Specific Immunotherapy Data At ASCO
6/1/2015
-
Targovax Announces Presentation Of Data From The Ongoing Phase I/II Clinical Study Of The RAS-Specific Therapeutic Cancer Vaccine TG01 In Resected Pancreatic Cancer At ASCO 2015 In Chicago
5/19/2015
-
Targovax To Expand On-Going Phase I/II CT-TG01-01 Pancreatic Cancer Study With A New Group Of Up To 13 Patients
3/9/2015
-
Targovax Appoints Øystein Soug As New CFO
2/26/2015
-
Targovax Strengthens Management Team With Algeta Hires
1/22/2015
-
Targovax Reports Completion Of Recruitment Of Patients In The Phase 1/2 Clinical Trial CT TG01-01
1/8/2015
-
Cancer Vaccine Specialist Targovax Appoints Gunnar Gårdemyr As New CEO
11/5/2014
-
Targovax Reaches Primary Endpoint For Ongoing Phase 1/2 Clinical Trial Of Pancreatic Cancer RAS Mutation Vaccine CT TG01-01
11/3/2014
-
Targovax TG01 Immunotherapy Reaches Phase 2a In Operable Pancreatic Cancer
2/6/2014